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Reply
Kayadibi et al raise a number of points that require clariﬁcation.
First, the purpose of this report was to see if an elevated
neutrophil/lymphocyte ratio (NLR) was associated with increased
probability of developing early cognitive dysfunction.
Second, Kayadibi et al question why “neutrophil and lympho-
cyte counts were not speciﬁed in detail according to the cognitive
state of patients.” Previous publications emphasize the importance
of the NLR ratio instead of using the individual neutrophil or
lymphocyte values.1-3 We followed suit in this study in only calcu-
lating the ratio. Previously, we found an association between early
cognitive dysfunction in asymptomatic patients undergoing carotid
endarterectomy (CEA), and monocytes (P ¼ .01).4
Third, we studied all patients undergoing CEAwhomet criteria
for inclusion or exclusion deﬁned in our previous publications.5,6
However, their suggestion thatoutliers“mayaffect the statistical ana-
lysis.” is wrong. Approximately 90% of all patients were admitted
from home, and the rest were recently admitted for a workup of
new neurologic deﬁcits. None of these patients were “septic, [with]
weight loss, massive hemorrhage and instrumental error..”
Fourth, the whole blood analyzer (WBA) used at this institu-
tion is the Sysmex XE-5000 (Sysmex, Kobe, Japan). Blood was
collected in standard tripotassium ethylenediaminetetraacetic acid
(K3EDTA) plastic tubes, and all samples were analyzed #8 hours of
collection. Because these results included patients enrolled during a
19-year period, we could not determine which WBA was used for
each sample. Even if there were differences over time in neutrophil
and lymphocyte counts based on the type of WBA, there is no reason
to think that the ratioswouldbedifferentover time for the samepatient.
Fifth, we used cutoffs previously used in other studies to place
our results in perspective with previous work. Kayadibi et al are
incorrect in asserting that by using a receiver operating characteristic
curve (ROC) analysis “the number. [of] the patients in each group
would have been equally distributed.” Cutoff optimization via ROC
analysis is based on optimization of sensitivity and speciﬁcity and
does not distribute groups equally. If we had wanted to obtain
equally distributed groups, we would have dichotomized at the me-
dian value; however, that would not require ROC analysis and would
not have necessarily resulted in a clinically meaningful variable.
Sixth, Kayadibi et al are mistaken in stating that a P value> .05
in univariate logistic regression automatically translates to a P value
> .05 in multiple logistic regression. A variable may be associated
with a nonsigniﬁcant P value in univariate logistic regression but still
have a signiﬁcant P value in multiple regression due to confounding
or modifying effects of other covariates. It is standard to use param-
eters with univariate P values# .2 in amultivariable statistical model
to avoid missing relevant statistical contributors to outcomes.7
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Regarding “Presentation, treatment, and outcome
differences between men and women undergoing
revascularization or amputation for lower extremity
peripheral arterial disease”
We read with interest the article by Lo et al1 describing the
recent trends in revascularization procedures for claudication
and critical limb ischemia (CLI) in the United States. Taken
together with the article by Wallace et al2 in the same issue of
the Journal of Vascular Surgery, these contributions give a broad
overview of the current landscape of interventions being per-
formed for advanced peripheral arterial disease (PAD) in the
United States. However, we believe that Lo et al1 have not fully
considered two key factors inﬂuencing the utilization of revascu-
larization procedures in their analysisdthe growing impact of
restenosis and the inﬂuence of provider specialty/training on
treatment choices.
As noted by the authors, the administrative data sets used
render them unable to link data longitudinally and, thus, to untan-
gle the key relationships between procedures, unique patients, and
unique limbs.
Recent observations using linked Medicare or registry data
provide important context for this report. First, restenosisd
wherein having longitudinal data in individual patients is criticald
represents a unique type of “disease progression” in PAD. The
burden of restenosis in PAD is growing as well as its effect on
the outcomes of secondary revascularizations.3 The data suggest
that the rise in secondary procedures may be a major factor under-
lying overall volume trends as well as the types of interventions be-
ing used. The risk factors for restenosis are poorly understood and
appear to vary between open and endovascular interventions.
Further, atherosclerotic occlusive disease and restenotic le-
sions are approached differently. The preference to perform a
certain type of intervention in a given subgroup (eg, women) could
be linked to the relative prevalence of restenotic vs primary disease
presentations. Although we have precious little in the way of level
1 evidence to support primary treatment choices in PAD, even less
data are available to deﬁne the optimal approach for most scenarios
of restenosis. For example, it seems plausible that provider spe-
cialty/training may inﬂuence the decision to repeat an endovascu-
lar intervention or move to an open bypass.
We further note recent data on the wide variation in utilization
and costs of invasive treatments for CLI in theMedicare population,
suggesting a major disconnect between resources, procedures, and
outcomes.4 Speciﬁcally, regions with the greatest spending and
highest proportion of endovascular procedures also had some of
the highest rates of amputation. So how do we interpret the volume
trends reported by Lo et al1 in this context?
That utilization rates of open and endovascular interventions
per se are not directly associated with clinical effectiveness or value
of care has become abundantly clear. Restenosisdand the reinter-
ventions and outcomes that followdmust be considered in every
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to robust data from prospective registries, such as the Vascular
Quality Initiative, and from randomized clinical trials to provide
longitudinal data on individual patients and the relationship of
treatment decisions to patient-centered outcomes. Only then will
we begin to move toward a better evidence framework for clinical
decision making in advanced PAD.
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